Test Code RPRT2 Rapid Plasma Reagin Titer, Serum
Specimen Required
Only orderable as a reflex. For more information see RPRT1 / Rapid Plasma Reagin (RPR) Screen with Reflex to Titer, Serum
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Secondary ID
616865Useful For
Determining the current disease status
Monitoring response to therapy for syphilis
This test cannot be used for testing spinal fluid specimens.
Method Name
Only orderable as a reflex. For more information see RPRT1 / Rapid Plasma Reagin (RPR) Screen with Reflex to Titer, Serum
Flocculation/Agglutination
Reporting Name
RPR Titer,SSpecimen Type
SerumSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 14 days |
Reject Due To
No specimen should be rejected.Clinical Information
Syphilis is caused by infection with the spirochete Treponema pallidum subspecies pallidum. The infection is systemic, and the disease is characterized by periods of latency. These features, together with the fact that T pallidum cannot be isolated in culture, mean that serologic techniques play a major role in the diagnosis and follow-up of treatment for syphilis.
Historically, the serologic testing algorithm for syphilis included an initial nontreponemal screening test, such as the rapid plasma reagin (RPR) or the VDRL tests. Because these tests measure the host's immune response to nontreponemal antigens, they lack specificity. Therefore, a positive result by RPR or VDRL requires confirmation by a treponemal-specific test, such as the fluorescent treponemal antibody-absorbed (FTA-ABS) or microhemagglutination (MHA-TP) assay. Although the FTA-ABS and MHA-TP assays are technically simple to perform, they are labor intensive and require subjective interpretation by testing personnel.
As an alternative to the traditional syphilis screening algorithm, many laboratories utilize the reverse syphilis screening algorithm. This algorithm starts with an automated treponemal assay to detect antibodies specific to T pallidum. If this screening assay is positive, the sample is reflexed for testing by RPR, which, if positive, is reported with a titer and is indicative of active or recent syphilis infection. If the RPR is negative, the sample is reflexed to a second treponemal assay, such as the T pallidum particle agglutination (TP-PA) assay. If the TP-PA is positive, this would indicate previously treated or late-stage syphilis infection. Alternatively, if the TP-PA is negative, the initial positive screen is interpreted as a false positive result.
Patients with primary or secondary syphilis are typically tested by RPR to monitor response to treatment. Typically, RPR titers decrease following successful treatment, but this may occur over a period of months to years. Additionally, testing of maternal and neonate serum, collected concurrently, by RPR can be used as an aid to diagnose congenital syphilis.
Reference Values
Only orderable as a reflex. For more information see RPRT1 / Rapid Plasma Reagin (RPR) Screen with Reflex to Titer, Serum
Negative
Interpretation
Negative:
No rapid plasma reagin (RPR) detected. Initial reactive RPR screen was likely a false-reactive result. Repeat testing if clinically indicated on a new specimen.Â
Positive:
Patients being monitored for response to therapy; a 4-fold or greater decrease in RPR titers between pre- and post-treatment samples indicates response to therapy. Patients evaluated for congenital syphilis: a 4-fold or higher RPR difference between neonate and maternal RPR titers suggests congenital syphilis.
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 2 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86593
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
RPRT2 | RPR Titer,S | 31147-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
616865 | RPR Titer,S | 31147-2 |